How much of the reported growth came from acquisitions rather than organic demand?

The gap between reported (20.9%) and organic (18.2%) growth in the quarter was about 2.7 percentage points after accounting for currency. Acquisitions actually reduced the organic comparison: the table shows a (4.0)% impact from certain acquisitions/divestitures, meaning organic growth excludes acquired sales that lacked a full comparable period. Organic growth, at 18.2%, is therefore the better measure of underlying performance.

Why was the quarter's EPS so far above guidance?

Adjusted EPS of $0.75 beat the $0.66-$0.68 guidance range, driven by strong sales above the top of the guided range and operating leverage: gross margin expanded and adjusted operating income rose to $1.350B from $1.012B. GAAP EPS of $0.45 was at the high end of its $0.43-$0.45 guidance, with the gap versus adjusted EPS mainly reflecting amortization, acquisition-related charges, and deferred tax items that the company excludes from its adjusted measure.

Is the full-year guidance a raise, and what does it imply for the rest of 2025?

The filing does not provide prior-year guidance for comparison, so whether this is a raise cannot be confirmed from this document alone. However, the implied rest-of-year math is informative: full-year reported growth of 15-17% combined with a strong Q1 of 20.9% implies deceleration later in the year, and the Q2 guide of 17.5-19.5% reported suggests moderation from Q1. Investors should compare these figures with prior guidance in earlier filings to assess the direction of revision.

What are the main risks highlighted for investors?

The release flags currency fluctuations, changing trade and tariff policies, reimbursement and regulatory conditions, supply chain disruptions, labor cost increases, clinical trial outcomes, and competition as key risks. Concentration in Cardiovascular growth, and in particular in the Cardiology franchise, raises execution and competitive exposure, while MedSurg's 5.3% organic growth shows relatively slower momentum in that segment.

What do the recent clinical and M&A developments mean for future growth?

The SINGLE SHOT CHAMPION trial results, published in NEJM, showed FARAPULSE superior to the Medtronic Arctic Front Advance cryoablation catheter in symptomatic paroxysmal AF, supporting share gains in pulsed field ablation. New trials such as ELEVATE-PF (persistent AF) and OPTION-A (combined PFA and WATCHMAN in Asia-Pacific) extend the franchise into new indications. The Bolt Medical acquisition adds intravascular lithotripsy for coronary and peripheral artery disease, and the pending SoniVie acquisition would expand into hypertension, but both are early-stage contributors and their financial impact is not quantified in the filing.

BSX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed April 23, 2025. Cited figures are marked; the original filing is the authoritative source.

Boston Scientific (BSX) reported a strong first quarter 2025, with net sales of $4.663 billion^a, up 20.9% on a reported basis, 22.2% operationally, and 18.2% organically year over year.

Growth was driven primarily by Cardiovascular, which rose 26.2% reported (25.6% organic), led by Cardiology and the FARAPULSE pulsed field ablation franchise, while MedSurg grew 11.7% reported (5.3% organic). The U.S. was the main engine at 31.1% growth, while international regions grew more modestly, with EMEA at 5.5% reported and Emerging Markets at 6.5%. GAAP net income attributable to common stockholders was $674 million^b, or $0.45 per diluted share, versus $0.33 a year earlier, and adjusted EPS was $0.75 versus $0.56.

Both results beat the company's own guidance ranges. Management raised the bar for the rest of the year. Full-year 2025 reported net sales growth is now guided to 15-17% and organic growth to 12-14%, with GAAP EPS of $1.86^c-$1.93 and adjusted EPS of $2.87-$2.94.

For the second quarter, the company expects reported growth of 17.5-19.5%, organic growth of 13-15%, and adjusted EPS of $0.71^d-$0.73. Portfolio activity included completing the Bolt Medical acquisition, a pending agreement to acquire SoniVie (a renal denervation technology for hypertension), and several clinical milestones, including the SINGLE SHOT CHAMPION trial published in NEJM. Investors should note that reported growth is materially boosted by acquisitions, and that GAAP earnings still carry meaningful amortization and restructuring charges.

Overall, the quarter shows strong top-line momentum and margin expansion, with gross profit rising to 68.8% of sales and operating income up roughly 36% year over year. The key debate going forward is whether Cardiovascular growth can be sustained against tougher comparisons and competitive pressure, and whether MedSurg can accelerate from its mid-single-digit organic pace.

02—Key points

Key Highlights

Net sales of $4.663B grew 20.9% reported, 22.2% operational, and 18.2% organic, all ahead of the company's guidance ranges of 17-19% reported and 14-16% organic.
GAAP EPS of $0.45 (diluted) and adjusted EPS of $0.75 both exceeded guidance, with adjusted EPS $0.09 above the high end of the $0.66-$0.68 range.
Cardiovascular sales rose 26.2% reported (25.6% organic) to $3.085B, driven by Cardiology (+29.8%), while MedSurg grew 11.7% reported but only 5.3% organically.
U.S. sales grew 31.1% to $2.960B, while EMEA (+5.5%), APAC (+8.2%), and LACA (+4.4%) lagged, with currency effects affecting reported growth in several regions.
Full-year 2025 guidance calls for 15-17% reported and 12-14% organic net sales growth, with adjusted EPS of $2.87-$2.94 and GAAP EPS of $1.86-$1.93.
Second-quarter guidance is 17.5-19.5% reported and 13-15% organic growth, with adjusted EPS of $0.71-$0.73, indicating continued strong momentum.
Strategic activity included completing the Bolt Medical acquisition and announcing the SoniVie acquisition (renal denervation for hypertension), subject to customary closing conditions.

03—Questions

Frequently Asked Questions

How much of the reported growth came from acquisitions rather than organic demand?
The gap between reported (20.9%) and organic (18.2%) growth in the quarter was about 2.7 percentage points after accounting for currency. Acquisitions actually reduced the organic comparison: the table shows a (4.0)% impact from certain acquisitions/divestitures, meaning organic growth excludes acquired sales that lacked a full comparable period. Organic growth, at 18.2%, is therefore the better measure of underlying performance.
Why was the quarter's EPS so far above guidance?
Adjusted EPS of $0.75 beat the $0.66-$0.68 guidance range, driven by strong sales above the top of the guided range and operating leverage: gross margin expanded and adjusted operating income rose to $1.350B from $1.012B. GAAP EPS of $0.45 was at the high end of its $0.43-$0.45 guidance, with the gap versus adjusted EPS mainly reflecting amortization, acquisition-related charges, and deferred tax items that the company excludes from its adjusted measure.
Is the full-year guidance a raise, and what does it imply for the rest of 2025?
The filing does not provide prior-year guidance for comparison, so whether this is a raise cannot be confirmed from this document alone. However, the implied rest-of-year math is informative: full-year reported growth of 15-17% combined with a strong Q1 of 20.9% implies deceleration later in the year, and the Q2 guide of 17.5-19.5% reported suggests moderation from Q1. Investors should compare these figures with prior guidance in earlier filings to assess the direction of revision.
What are the main risks highlighted for investors?
The release flags currency fluctuations, changing trade and tariff policies, reimbursement and regulatory conditions, supply chain disruptions, labor cost increases, clinical trial outcomes, and competition as key risks. Concentration in Cardiovascular growth, and in particular in the Cardiology franchise, raises execution and competitive exposure, while MedSurg's 5.3% organic growth shows relatively slower momentum in that segment.
What do the recent clinical and M&A developments mean for future growth?
The SINGLE SHOT CHAMPION trial results, published in NEJM, showed FARAPULSE superior to the Medtronic Arctic Front Advance cryoablation catheter in symptomatic paroxysmal AF, supporting share gains in pulsed field ablation. New trials such as ELEVATE-PF (persistent AF) and OPTION-A (combined PFA and WATCHMAN in Asia-Pacific) extend the franchise into new indications. The Bolt Medical acquisition adds intravascular lithotripsy for coronary and peripheral artery disease, and the pending SoniVie acquisition would expand into hypertension, but both are early-stage contributors and their financial impact is not quantified in the filing.

04—Continue

← View all 8-K filings